STOCK TITAN
  1. Home
  2. News
  3. AGLE

Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

AUSTIN, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in two presentations at the World Orphan Drug Congress USA 2020 being held virtually August 24-27, 2020.

Presentation Details

Panel Title: Stronger Together: Continuing industry and patient partnerships to ensure inclusion of patient voice along the full continuum of development, from pre-clinical through commercialization
Date/Time: August 24 at 9:10 a.m. EDT
Moderator: Michael C. Hanley, Aeglea’s chief commercial officer

Presentation Title: Next generation human enzymes: Innovative solutions for patients with rare diseases
Date/Time: August 25 at 12:50 p.m. EDT
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer

The company presentation will be available for download on the Presentations & Events section of the Company’s website.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. The Company initiated a Phase 1/2 clinical trial of ACN00177 for the treatment of Homocystinuria in the second quarter of 2020. Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit http://aegleabio.com.

Media Contact:
Kelly Boothe, Ph.D.
Director, Corporate Communications
Aeglea BioTherapeutics
512.399.5458
media@aegleabio.com

Investor Contact:
Joey Perrone
Senior Director, Finance & Investor Relations
Aeglea BioTherapeutics
investors@aegleabio.com


Stock AGLE logo
Spyre Therapeutics, Inc.

NASDAQ:AGLE

AGLE Rankings

N/A Ranked by Market Cap
#4882 Ranked by Stock Gains
N/A Ranked by Dividends

AGLE Latest News

Nov 27, 2023
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD
Nov 22, 2023
Aeglea BioTherapeutics Announces Grants of Inducement Awards
Nov 9, 2023
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 3, 2023
Aeglea BioTherapeutics Announces Grants of Inducement Awards
Oct 30, 2023
Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences

AGLE Stock Data

48.63M
1.92M
3.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Austin

About AGLE

aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f